Skip to main content

Table 3 Utility scores

From: Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

Parameters Utility Time with Disease Ranges References
Screening Pap 0.98 1 months 2 weeks – 2 months Myers et al39 and Insinga et al40
ASCUS pap 0.94 1 month 2 weeks-2 months  
>= LSIL pap 0.91 2 months 1–4 months  
Warts 0.91 2 months 1–4 months  
CIN 1 0.91 0.96 2 months 10 months 2–4 months 0–10 months  
CIN 2–3 0.87 2 months 1–4 months  
FIGO I 0.76 5 years 1–5 years  
FIGO II 0.67 5 years 1–5 years  
FIGO III 0.67 5 years 1–5 years  
FIGO IV 0.67 5 years 1–5 years